Master Classes
Master Classes are deeper dives into a particular topic that require additional time and instruction. This year we will hold three Master Classes on the following topics: Theranostics, Leadership Bootcamp for Early Career Faculty and Medical Marijuana.
Radiopharmaceutical Therapy
$150 - Members/Nonmember
Free - Residents/Students
Join us for a 3-hour training workshop designed to teach clinical radiation oncologists everything they need to know to expand their practice into radiopharmaceutical therapy. Many new radiopharmaceutical therapies (RPTs) are now approved and many others are emerging for treatment of prostate cancer, neuroendocrine cancers and other cancers. Radiation oncologists are experts regarding the benefits and risks associated with various cancer therapeutic options and are perfectly positioned to help patients make the best choice for their particular situation, including the use of RPTs. Radiation oncologists are certified to deliver these RPTs but many lack specific and updated training and therefore underutilize them.
This workshop will provide a refresher on relevant physics, pharmacology, and radiobiology, as well as offer logistical and practical training in clinical use of radiopharmaceuticals. It will include specific breakout sessions on Ra-223, Lu-177 DOTATATE, Lu-177 PSMA agents, I-131 MIBG and Y-90 Microspheres and cover important infrastructure, workflow and financial considerations. This special training workshop will enable radiation oncologists to provide the highest quality of patient-centered care in the use of RPTs.
Schedule of Events - Segment I: Saturday, October 24 - 9:00 a.m. - 10:30 a.m.
Time |
Topic |
Speaker(s) |
9:00 a.m. – 9:20 a.m. |
Introduction to Radiopharmaceutical Therapy |
Dan Pryma, MD |
9:20 a.m. – 9:45 a.m. |
- Basics of Physics and Radiobiology for RPTs
|
Stephen Graves, PhD
Ana Kiess, MD, PhD |
9:45 a.m. – 10:10 a.m. |
Ra-223 for mCRPC
- Background and key trials
- Patient selection
- Toxicities and follow-up
- Logistics of new practice
- Example of prep, injection and rad safety
|
Richard Stock, MD |
10:10 a.m. – 10:25 a.m. |
Q&A |
All Faculty |
10:25 a.m. – 10:45 a.m. |
Break |
|
Schedule of Events - Segment II: Saturday, October 24 - 10:45 a.m. - 12:15 p.m.
Time |
Topic |
Speaker(s) |
10:45 a.m. – 11:15 a.m. |
Lu-DOTATATE for NETs
- Background and key trials
- Patient selection
- Toxicities and follow-up
- Logistics of new practice
- Example of prep, infusion and rad safety
|
Lisa Bodei, MD, PhD |
11:15 a.m. – 11:25 a.m. |
Q&A |
Lisa Bodei, MD, PhD |
11:25 a.m. – 11:55 a.m. |
Lu-PSMA for mCRPC
- Background and key trials
- Patient selection
- Toxicities and follow-up
- Logistics of new practice
- Example of prep, injection and rad safety
|
Michael Morris, MD |
11:55 a.m. – 12:05 p.m. |
Q&A |
Michael Morris, MD |
12:05 p.m. – 12:15 p.m. |
Wrap-up |
John Buatti, MD |
Professional Development: Leadership and Emotionally Intelligent Communication
$50 - Members/Nonmember/Residents/Students
The pace of the rapidly accelerating changes in the health care system has led to increased stress and administrative burden in the radiation oncology workplace, leading to the potential for increased dysfunction and communication breakdown in the physician/patient and physician/team relationship. Strong leadership skills at the level of the individual and team are needed to maintain performance and morale without burnout long term. This special session will focus on how radiation oncologists can lead themselves and others to professional success with emphasis on how they can also enhance their own interpersonal communication skills. This session will integrate short lectures with interactive exercises designed to help each participant understand how to optimize their own leadership/communication priorities. To reinforce how these concepts translate to practice, a diverse panel of radiation oncology leaders will be included and will share their experiences in dynamic Q&A sessions.
Schedule of Events - Session I: Sunday, October 25 - 1:00 p.m. - 2:30 p.m.
Time |
Event |
1:00 p.m. – 1:10 p.m. |
Welcome and Introduction
Raphael Yechieli, MD |
1:10 p.m. – 1:35 p.m. |
Leading Self Presentation
Neha Vapiwala, MD |
1:35 p.m. – 1:55 p.m. |
Values Exercise
Raphael Yechieli, MD |
1:55 p.m. – 2:10 p.m. |
Leading Others Presentation
John Suh, MD |
2:10 p.m. – 2:30 p.m. |
Breakout |
2:30 p.m. – 2:50 p.m. |
Panel Q&A
Moderator: Rahul Tendulkar, MD
Panelists:
Raphael Yechieli, MD
Neha Vapiwala, MD
John Suh, MD
|
Schedule of Events - Session II: Sunday, October 25 - 2:45 p.m. - 4:15 p.m.
Time |
Event |
2:45 p.m. – 2:55 p.m. |
Introduction
Sarah Hoffe, MD |
2:55 p.m. – 3:05 p.m. |
Intro to DiSC: Understanding Communication Styles
Gabi Harmon, PhD |
3:05 p.m. – 3:20 p.m. |
DSC Exercise (Breakout)
Gabi Harmon, PhD |
3:20 p.m. - 3:40 p.m. |
Putting your DiSC Results in Context
Gabi Harmon, PhD |
3:40 p.m. – 4:15 p.m. |
Leadership Panel Discussion and Q&A
Moderators: Sarah Hoffe, MD and Gabi Harmon, PhD
Panelists:
Lou Harrison, MD
Jessica Frakes, MD
Charles Thomas, MD
Mike Steinberg, MD |
Cannabis in Cancer Care
$100 - Members/Nonmember/Residents/Students
With medicinal and recreational cannabis becoming more widely available across the country, use among cancer patients continues to increase. A survey of oncologists demonstrated that although many believe that cannabis might be a useful adjuvant to conventional cancer care, only a third of the respondents feel informed enough to guide their patients. This session will review the history of cannabis as medicine through its current status as a Schedule I substance. The endocannabinoid system of cannabinoid receptors and endogenous cannabinoids will be described. The known published therapeutic effects of cannabis and cannabinoids in patients with cancer will be reviewed. Cannabidiol (CBD) has emerged as a most favored cannabinoid because, unlike delta-9-tetrahydrocannabinol (THC), it is not “psychoactive”. The current CBD knowledgebase will be explained. The lack of information on the selective therapeutic benefits of various cannabis strains or ratios of THC:CBD will be highlighted. The session will include a discussion of whether data suggests that cannabis can increase the risk of cancer or have clinically significant anticancer activity.
Schedule of Events - Part 1 - Monday, October 26 - 1:00 p.m. - 2:30 p.m.
Time |
Presentation Title/Speaker |
1:00 p.m. - 1:10 p.m. |
Welcome and Introduction
Donald Abrams. MD |
1:10 p.m. – 1:55 p.m. |
Cannabis as Medicine: History, Mechanism of Action and Cannabinoids
Donald Abrams. MD |
1:55 p.m. - 2:30 p.m. |
National Academies of Sciences, Medicine and Engineering’s Health Effects of Cannabis and Cannabinoids: Report on the Report
Donald Abrams. MD |
Schedule of Events - Part 2 - Monday, October 26 - 2:45 p.m. - 4:15 p.m.
Time |
Presentation Title/Speaker |
2:45 p.m. -3:45 p.m. |
Cannabis in Cancer Care: Symptom Management and Review of Possible Anti-cancer Activity
Donald Abrams. MD |
3:45 p.m. - 4:15 p.m. |
Discussion/Q&A
Donald Abrams. MD |